Works matching IS 00071048 AND DT 2015 AND VI 170 AND IP 5


Results: 19
    1
    2
    3
    4

    Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20<sup>+</sup> lymphoid malignancies.

    Published in:
    British Journal of Haematology, 2015, v. 170, n. 5, p. 669, doi. 10.1111/bjh.13487
    By:
    • Roberts, Andrew W.;
    • Advani, Ranjana H.;
    • Kahl, Brad S.;
    • Persky, Daniel;
    • Sweetenham, John W.;
    • Carney, Dennis A.;
    • Yang, Jianning;
    • Busman, Todd B.;
    • Enschede, Sari H.;
    • Humerickhouse, Roderick A.;
    • Seymour, John F.
    Publication type:
    Article
    5
    6
    7
    8
    9
    11
    12
    13
    14
    15
    16
    17
    18
    19